-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $310

Benzinga·10/07/2026 14:22:02
Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $296 to $310.